ImaginAb, GE Imanet ink PET agreement

ImaginAb and GE Imanet have signed a master service agreement to provide PET imaging agents for drug research.

Inglewood, Calif.-based ImaginAb will utilize GE Imanet’s high sensitivity and high resolution PET infrastructure to develop diagnostic imaging agents based on recombinant antibody fragments. U.K.-based GE Imanet provides assistance for its proof-of-concept radiochemistry, pre-clinical and clinical imaging PET network, which includes over 40 PET research tracers.

Around the web

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.